What is CMLtinib (Imatinib Mesylate)
CMLtinib (Imatinib Mesylate) 400 mg capsules IP is a protein – tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase created by the Philadelphia chromosome abnormally in Chronic Myeloid Leukemia (CML)
M/s SMIQ Pharma
400 mg Tablets
- CMLtinib is indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive Chronic Myeloid Leukemia (CML) in chronic phase.
- CMLtinib is indicated for the treatment of patients with Philadelphia chromosome positive Chronic Myeloid Leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of Interferon-alpha therapy.
- CMLtinib is also indicated for the treatment of pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplant or who are resistant to Interferon-alpha therapy
- CMLtinib is also indicated for the treatment of patients with kit (CD 117) positive unresectable and/ or metastatic malignant Gastro-Intestinal Stromal Tumors (GIST)
For treatment related information, please consult your treating Physician.
CMLtinib 400 mg (Imatinib Mesylate) is available as follows:
Each hard gelatine capsule of 400 mg supplied in a bottle of Ten (10) capsules
Storage and handling
Store at room temperature
Protect CMLtinib from light
How do we source the Drug?
SMIQ Pharma will assist in sourcing the drug through its efficient network, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.
Contact us @ +91 7678048225 or by email firstname.lastname@example.org.